Glycomimetics Inc (GLYC) 10-K Annual Report March 2019

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2018	Feb. 28, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Registrant Name	GLYCOMIMETICS INC
Entity Central Index Key	0001253689
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		43,168,969
Entity Public Float			$ 538.3

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1253689/000155837019001537/glyc-20181231x10k.htm

View differences made from one year to another to evaluate Glycomimetics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Glycomimetics Inc.

Continue

Assess how Glycomimetics Inc's management team is paid from their Annual Proxy

Glycomimetics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

Other

Filter Subcategory:

All

Expense

Product

Income

Earnings

Geography

Other

Inside Glycomimetics Inc's 10-K Annual Report:

Financial - Expense Highlight
In assessing cash used in operating activities, we consider several principal factors: (i) net loss for the period; (ii) adjustments for non-cash charges including stock-based compensation expense and depreciation and amortization of property and equipment; and (iii) the extent to which receivables, accounts payable and other liabilities, or other working capital components increase or decrease.

Financial - Expense Highlight
These prepaid expenses were offset by a decrease in costs for clinical expenses related to uproleselan and GMI-1359.
Other - Other Highlight
At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and identify, as a performance obligation, and assess whether each promised good or service is distinct.
Financial - Expense Highlight
In addition, personnel-related and stock-based compensation expenses increased in 2017 by approximately $0.9 million due to an increase in labor-related costs and stock-based compensation expense.
Revenue - Product Highlight
In March 2016, we entered into an at-the-market sales agreement with Cowen to sell shares of our common stock having an aggregate offering price of up to $40.0 million through Cowen acting as our sales agent.
Other - Other
We received an additional $19.7...Read more
Financial - Income
Other income increased by $2.6...Read more
Revenue - Product
We are also eligible to...Read more
Financial - Earnings
We cannot assure you that...Read more
Financial - Expense
We have selected the Black-Scholes-Merton...Read more
Revenue - Product
To date, we have financed...Read more
Revenue - Product
To determine revenue recognition for...Read more
Other - Other
Net cash provided by financing...Read more
Other - Other
Financing Activities Net cash provided...Read more
Financial - Expense
Personnel-related and stock-based compensation expenses...Read more
Other - Other
The foregoing table does not...Read more
Financial - Expense
Personnel-related and stock-based compensation expenses...Read more
Revenue - Product
Effective January 1, 2018, we...Read more
Financial - Expense
We record costs for some...Read more
Other - Other
The license also covers specified...Read more
Revenue - Product
Under the agreement, Pfizer made...Read more
Revenue - Product
Royalties: For arrangements that include...Read more
Financial - Expense
The following table summarizes our...Read more
Other - Other
The IPO provided us with...Read more
Revenue - Product
In September 2017, we entered...Read more
Revenue - Geography
In May 2017, the European...Read more
Revenue - Product
Substantially all of our revenue...Read more
Revenue - Product
The transaction price is then...Read more
Other - Other
If we raise additional funds...Read more
Financial - Expense
The capitalized amounts are expensed...Read more
Revenue - Product
We have generated cumulative revenue...Read more
Financial - Expense
We expect our research and...Read more
Revenue - Geography
In December 2018, at the...Read more
Other - Other
We will determine which programs...Read more
Financial - Expense
Our primary uses of capital...Read more
Other - Other
Our initial research and development...Read more
Revenue - Product
Prior to our IPO, we...Read more
Revenue - Product
Under Topic 606, an entity...Read more
Financial - Expense
Payments for these activities are...Read more
Other - Other
While our significant accounting policies...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Glycomimetics Inc provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Ticker: GLYC
CIK: 1253689
Form Type: 10-K Annual Report
Accession Number: 0001558370-19-001537
Submitted to the SEC: Wed Mar 06 2019 3:30:07 AM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations